paroxetine has been researched along with Cardiovascular Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Cheng, S; Guo, S; Xu, H | 1 |
| Backman, JT; Kautiainen, H; Mäenpää, J; Neuvonen, M; Neuvonen, PJ; Niemi, M; Volotinen-Maja, M | 1 |
| Crain, AL; Godlevsky, OV; O'Connor, PJ; Wei, F; Whitebird, RR | 1 |
| Coffey, DB; John, N; Potter, PO | 1 |
| Bitter, I; Demitrack, MA; Detke, MJ; Mallinckrodt, CH; McNamara, RK; Wiltse, CG | 1 |
1 review(s) available for paroxetine and Cardiovascular Diseases
| Article | Year |
|---|---|
Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Cardiovascular Diseases; China; Citalopram; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2019 |
1 trial(s) available for paroxetine and Cardiovascular Diseases
| Article | Year |
|---|---|
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Weight; Cardiovascular Diseases; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Electrocardiography; Female; Hemodynamics; Humans; Longitudinal Studies; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Sexual Dysfunction, Physiological; Thiophenes | 2004 |
3 other study(ies) available for paroxetine and Cardiovascular Diseases
| Article | Year |
|---|---|
Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops.
Topics: Adult; Area Under Curve; Cardiovascular Diseases; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Eye; Heart Rate; Humans; Male; Ophthalmic Solutions; Paroxetine; Risk; Timolol; Young Adult | 2014 |
Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study.
Topics: Adult; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Risk Factors; Sertraline; Time Factors | 2009 |
Onset of abnormal movements and cardiovascular symptoms after acute change in complex polypharmacy in a child with attention-deficit/hyperactivity disorder and mood symptoms.
Topics: Adrenergic alpha-Agonists; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Asthma; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Chest Pain; Child; Dyskinesia, Drug-Induced; Family; Female; Guanfacine; Humans; Lithium Chloride; Male; Mood Disorders; Neuropsychological Tests; Obesity; Paroxetine; Piperazines; Polypharmacy; Pregnancy; Prenatal Exposure Delayed Effects; Psychomotor Agitation; Quinolones; Selective Serotonin Reuptake Inhibitors; Smoking; Social Environment | 2012 |